Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Melanoma 14Carcinoma, Renal Cell 10Carcinoma, Non-Small-Cell Lung 7Carcinoma, Transitional Cell 4Neoplasms 3Neoplasm Metastasis 3Clear-cell metastatic renal cell carcinoma 3Carcinoma, Hepatocellular 3Thyroid Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Prostatic Neoplasms 2Nasopharyngeal Carcinoma 2Myelodysplastic Syndromes 2Multiple Myeloma 2Lung Neoplasms 2Leukemia, Myeloid, Acute 2Kidney Neoplasms 2Brain Neoplasms 2Vulvar Neoplasms 1Urogenital Neoplasms 1Urinary Bladder Neoplasms 1Urethral Neoplasms 1Urachal adenocarcinoma 1Triple Negative Breast Neoplasms 1Thyroid Carcinoma, Anaplastic 1Thyroid Cancer, Papillary 1Somatostatinoma 1Skin Neoplasms 1Seminoma 1Sarcoma 1

Interventions

Temozolomide 18Radiation 7Magnetic Resonance Spectroscopy 7Radiotherapy 6Specimen Handling 4Lomustine 4Bevacizumab 4Aminolevulinic Acid 3veliparib 2trametinib 2lutetium Lu 177 dotatate 2dabrafenib 2azeliragon 2Surgical Procedures, Operative 2Receptors, Interleukin-8B 2Nivolumab 2D2C7-(scdsFv)-PE38KDEL 2Carboplatin 2Biopsy 2varlilumab 1ulixertinib 1tinostamustine 1selinexor 1ruxolitinib 1ribociclib 1relatlimab 1regorafenib 1peposertib 1pembrolizumab 1olaparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Glioblastoma × Ipilimumab × 30 days × Clear all
NCT04145115 2026-05-29

A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Elevated Mutational Burden

National Cancer Institute (NCI)

Phase 2 Active not recruiting
37 enrolled
CNS

Astrocytoma, Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡